PMID: 28965575 Thomson CD, Chisholm A, McLachlan SK, Campbell JM
Convincing evidence that GLP-1R stimulating drugs are associated with anti-inflammatory, neurotrophic, and neuroprotective properties in preclinical models of NDD has led to trials of these drugs in the NDD clinic
This becomes crucial when billing for services like: In-office hemoglobin tests Nutrient injections (e.g., B12 shots) Chronic disease management When payers match your claims to your scope of services, any mismatch can result in claim denial, even if the diagnosis code is correct
The washout period was estimated to be equivalent to five or more times the period of the bioflavonoid half-life in the blood
Thousands of people are overpaying for the same GLP-1 treatment
Despite this evidence, acetyl-l-carnitine is currently not approved as a drug for any indication in the United States